A Proof-of-concept Study to Assess the Effect of (+)-SJ000557733 (SJ733) Against Early Plasmodium Falciparum Blood Stage Infection in Healthy Participants
Latest Information Update: 05 Nov 2021
At a glance
- Drugs SJ 733 (Primary)
- Indications Falciparum malaria
- Focus Adverse reactions; Proof of concept; Therapeutic Use
- 01 Aug 2020 Results published in The Lancet Infectious Diseases
- 06 Mar 2018 Status changed from recruiting to completed.
- 19 Aug 2016 New trial record